Given the recent classification of gliomas based on IDH mutation and the long time course of this disease, the article emphasizes the need for a thoughtful and comprehensive strategy to study patient outcomes and devise methods of cognitive risk reduction. This evidence concerns the gene IDH1 and central nervous system cancer.